Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 300-491-4 | CAS number: 93940-93-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2017-04-18 to 2017-05-25
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Version / remarks:
- 2002
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- Bis[N-(2-hydroxyethyl)-N-methylglycinato-N,O,ON]copper
- EC Number:
- 300-491-4
- EC Name:
- Bis[N-(2-hydroxyethyl)-N-methylglycinato-N,O,ON]copper
- Cas Number:
- 93940-93-3
- Molecular formula:
- C10H20CuN2O6
- IUPAC Name:
- bis[N-(2-hydroxyethyl)-N-methylglycinato-N,O,ON]copper
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- WISTAR rats Crl: WI(Han)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Housing and Feeding Conditions:
- Full barrier in an air-conditioned room
- Temperature: 22 ± 3 °C
- Relative humidity: 55 ± 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: 10 x per hour
- Free access to Altromin 1324 maintenance diet for rats and mice
- Free access to tap water, sulphur acidified to a pH value of approximately 2.8 (drinking water, municipal residue control, microbiological controls at regular intervals)
- The animals were kept in groups in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding
- Certificates of food, water and bedding are filed for two years at BSL Munich and afterwards archived at Eurofins Munich
- Adequate acclimatisation period (at least five days) under laboratory conditions
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- Aqua ad injectionem
- Details on oral exposure:
- The test item was administered at a single dose by gavage using a feeding tube.
The test item was administered at a dose volume of 10 mL/kg body weight. - Doses:
- The starting dose was selected to be 300 mg/kg body weight (step 1 and step 2)
step 3 performed with 2000 mg/kg body weight - No. of animals per sex per dose:
- 3 + 3 females step 1 and 2
3 females step 3 - Control animals:
- no
- Details on study design:
- - Observation Period:
The surviving animals were observed for 14 days after dosing for general clinical signs, morbidity and mortality.
- Weight Assessment:
The animals were weighed on day 1 (prior to the administration) and on days 8 and 15.
- Clinical Examination:
A careful clinical examination was made several times on the day of dosing (at least once during the first 30 minutes and with special attention given during the first 4 hours post-dose). Thereafter, the animals were observed for clinical signs once daily until the end of the observation period. All abnormalities were recorded.
Cageside observations included changes in the skin and fur, eyes and mucous membranes. Also respiratory, circulatory, autonomic and central nervous systems and somatomotor activity and behaviour pattern were examined. Particular attention was directed to observations of tremor, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
- Pathology:
At the end of the observation period the surviving animals were sacrificed with an overdosage of pentobarbital injected intraperitoneally at a dosage of 250-400 mg/kg bw.
All animals were subjected to gross necropsy and examined macroscopically for gross pathological changes. In the absence of gross pathological changes no tissues were preserved for a possible histopathological evaluation.
- Evaluation of Results:
Results were interpreted according to OECD Guideline 423, Annex 2 and GHS.
Individual reactions of each animal were recorded at each time of observation.
Toxic response data were recorded by dose level.
Nature, severity and duration of clinical observations were described.
The body weight changes were summarised in a tabular form.
Necropsy findings were described.
With few exceptions, data were captured using the validated departmental computerised system E WorkBook (version 10.1.2, ID Business Solutions Ltd.). - Statistics:
- n.a.
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50 cut-off
- Effect level:
- ca. 500 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Two animals treated with the test item at a dose of 300 mg/kg bw (step 1 and 2) died spontaneously within 3 days post dosing.
All animals treated with the test item at a dose of 2000 mg/kg bw (step 3) died spontaneously within 30 - 60 minutes post dosing. - Clinical signs:
- The most relevant clinical findings in the animals treated with the test item at a dose of 300 mg/kg bw were reduced spontaneous activity, sunken flunks, piloerection, half eyelid closure, slow movements and hunched posture.
The most relevant clinical findings in the animals treated with the test item at a dose of 2000 mg/kg bw were reduced spontaneous activity, ataxia, half eyelid closure, abnormal breathing, prone position, sunken flunks and opisthotonus. - Body weight:
- 300 mg/kg bw: Throughout the 14-day observation period, the weight gain of the surviving animals was within the normal range of variation for this strain.
- Gross pathology:
- At necropsy, no macroscopic findings were observed in any animal of any step.
Any other information on results incl. tables
Results per Step
Step | Sex / No. | Starting Dose (mg/kg bw) | Number of Animals | Number of Intercurrent Deaths |
1 | Female / 1 - 3 | 300 | 3 | 1 |
2 | Female / 4 - 6 | 300 | 3 | 1 |
3 | Female / 7 - 9 | 2000 | 3 | 3 |
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- The median lethal dose of the test item after a single oral administration to female rats, observed over a period of 14 days is: LD50 cut-off (rat): 500 mg/kg bw.
- Executive summary:
The purpose of this study was to assess the toxicity of the test item when administered to rats as a single oral dose.
The study was carried out in accordance with OECD Guideline No. 423 and EPA Health Effects Test Guideline OPPTS 870.1100. The study was performed according to GLP regulations.
Two groups, each of three female WISTAR Crl: WI(Han) rats, were treated with the test item by oral gavage administration at a dosage of 300 mg/kg body weight. The test item was suspended with aqua ad injectionem (sterile water) at a concentration of 0.03 g/mL and administered at a dose volume of 10 mL/kg.
One group of three female WISTAR Crl: WI(Han) rats, was treated with the test item by oral gavage administration at a dosage of 2000 mg/kg body weight. The test item was suspended with aqua ad injectionem (sterile water) at a concentration of 0.2 g/mL and administered at a dose volume of 10 mL/kg.
All animals used in the study were allowed to acclimatise to the laboratory conditions for at least 5 days. The animals were observed on delivery, on inclusion in the study and before administration for mortality/morbidity and other clinical signs. All animals were examined for clinical signs several times on the day of dosing and once daily until the end of the observation period. Their body weights were recorded on day 1 (prior to the administration) and on days 8 and 15. All animals were necropsied and examined macroscopically.
Two animals treated with the test item at a dose of 300 mg/kg bw (step 1 and 2) died spontaneously within 3 days post dosing. All remaining animals survived until the end of the study. The most relevant clinical findings in the animals treated with the test item at a dose of 300 mg/kg bw were reduced spontaneous activity, sunken flunks, piloerection, half eyelid closure, slow movements and hunched posture. Throughout the 14-day observation period, the weight gain of the surviving animals was within the normal range of variation for this strain.
All animals treated with the test item at a dose of 2000 mg/kg bw (step 3) died spontaneously within 30 - 60 minutes post dosing. The most relevant clinical findings in the animals treated with the test item at a dose of 2000 mg/kg bw were reduced spontaneous activity, ataxia, half eyelid closure, abnormal breathing, prone position, sunken flunks and opisthotonus. At necropsy, no macroscopic findings were observed in any animal of any step.
The median lethal dose of the test item after a single oral administration to female rats, observed over a period of 14 days is: LD50cut-off (rat): 500 mg/ kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
